Detection of linezolid-resistant staphylococcus aureus with 23S rRNA and novel L4 riboprotein mutations in a cystic fibrosis patient in Spain

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 5, 2013, Pages 2428-2429

  Román, Federico ^a   Roldán, Carolina ^b   Trincado, Pilar ^a   Ballesteros, Carmen ^b   Carazo, Concepción ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b Servicio de Microbiologia   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; BACTERIAL PROTEIN; CLINDAMYCIN; COLISTIN; ERYTHROMYCIN; L4 RIBOPROTEIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; OXACILLIN; RNA 23S; TEICOPLANIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ADOLESCENT; AMINO ACID SEQUENCE; ANTIBIOTIC SENSITIVITY; CASE REPORT; CYSTIC FIBROSIS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; FEMALE; GENE MUTATION; GRAM NEGATIVE INFECTION; HUMAN; LETTER; LINEZOLID RESISTANT STAPHYLOCOCCUS AUREUS; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; SPAIN; SPUTUM CULTURE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STENOTROPHOMONAS MALTOPHILIA; STENOTROPHOMONAS MALTOPHILIA INFECTION;

ACETAMIDES; ADOLESCENT; ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; MUTATION; OXAZOLIDINONES; RIBOSOMAL PROTEINS; RNA, RIBOSOMAL, 23S; SPAIN; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 84876272797     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00208-13     Document Type: Letter

References (10)

1. Endimiani A, Blackford M, Dasenbrook EC, Reed MD, Bajaksouszian S, Hujer AM, Rudin SD, Hujer KM, Perreten V, Rice LB, Jacobs MR, Konstan MW, Bonomo RA. 2011. Emergence of linezolid-resistant Staphylococcus aureus after prolonged treatment of cystic fibrosis patients in Cleveland, Ohio. Antimicrob. Agents Chemother. 55:1684-1692.
2. Gu B, Kelesidis T, Tsiodras S, Hindler J, Humphries RM. 2013. The emerging problem of linezolid-resistant Staphylococcus. J. Antimicrob. Chemother. 68:4-11.
3. Keel RA, Schaeftlein A, Kloft C, Pope JS, Knauft RF, Muhlebach M, Nicolau DP, Kuti JL. 2011. Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis. Antimicrob. Agents Chemother. 55:3393-3398.
4. Clinical and Laboratory Standards Institute. 2011. Performance standards for antimicrobial susceptibility testing. Twenty-first informational supplement M100-S21. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Vindel A, Cuevas O, Cercenado E, Marcos C, Bautista V, Castellares C, Trincado P, Boquete T, Pérez-Vázquez M, Marín M, Bouza E, Spanish Group for the Study of Staphylococcus. 2009. Methicillin-resistant Staphylococcus aureus in Spain: molecular epidemiology and utility of different typing methods. J. Clin. Microbiol. 47:1620-1627.
6. Kehrenberg C, Schwarz SS. 2006. Distribution of florfenicol resistance genes fexA and cfr among chloramphenicol-resistant Staphylococcus isolates. Antimicrob. Agents Chemother. 50:1156-1163.
7. Pillai SK, Sakoulas G, Wennersten C, Eliopoulos GM, Moellering RC, Jr, Ferraro MJ, Gold HS. 2002. Linezolid resistance in Staphylococcus aureus: characterization and stability of resistant phenotype. J. Infect. Dis. 186:1603-1607.
8. Mendes RE, Deshpande LM, Farrell DJ, Spanu T, Fadda G, Jones RN. 2010. Assessment of linezolid resistance mechanisms among Staphylococcus epidermidis causing bacteraemia in Rome, Italy. J. Antimicrob. Chemother. 65:2329-2335.
9. Flamm RK, Mendes RE, Ross JE, Sader HS, Jones RN. 2013. Linezolid surveillance results for the United States: LEADER Surveillance Program 2011. Antimicrob. Agents Chemother. 57:1077-1081.
10. Prunier AL, Trong HN, Tande D, Segond C, Leclerq R. 2005. Mutation of L4 ribosomal protein conferring unusual macrolide resistance in two independent clinical isolates of Staphylococcus aureus. Microb. Drug Resist. 11:18-20.